Abstract:Purpose: Accumulating evidence that apolipopro-tein B (apoB) plays a critical role in predicting coronary heart disease (CHD) and future outcomes. The 2019 European Society of Cardiology/European Atherosclerosis Society guidelines suggest that apoB can be an alternative to non-HDL-C or LDL-C in patients with high triglyceride levels, diabetes, obesity, metabolic syndrome, or very low LDL-C levels. This study explores whether apoB can also serve as predictive value for long-term major adverse cardiovascular events (MACEs) in normal people and specific coronary atherosclerosis patients.Methods: A total of 826 patients were followed up over 10 years, and the risk factors for MACEs were retrospectively analyzed in patients with CHD and particular subpopulations. All statistical analyses were performed in R software. Cox regressions were performed to assess independent risk factors of long-term MACEs in the atherosclerosis group and CHD subgroups. Kaplan-Meier survival curves were used to evaluate the survival rate for patients in different apoB quartiles, and receiver-operating characteristic curves were used to compare apoB and other lipids in predicting the presence of long-term MACE.Findings: apoB could be a "risk-enhancing factor" in patients with coronary atherosclerosis disease, whereas in the Normal population, LDL-C still acted as a major risk factor for predicting MACEs. apoB was a good risk predictor for long-term cardiovascular events in coronary atherosclerosis (AS) patients, including the AS group and CHD subpopulations (including CHD + triglyceride >2.3 mmol/L, CHD + diabetes mellitus, CHD + body mass index >25 kg/m2, or CHD + metabolic syndrome). In patients with CHD whose condition was complicated with diabetes, obesity, and metabolic syndrome, apoB performed better than other lipids in predicting the presence of myocardial infarction, hospitalization due to angina, and cardiac death. Despite achieving optimal LDL-C or non-HDL-C levels, patients with CHD are still at risk of worse survival if they are unable to reach a low apoB level (lower cut points such as 65 mg/dL).Implications: More attention should be paid to special populations with residual elevations of athero-genic particle numbers, and greater focus should be placed on lowering baseline apoB to achieve long-term benefits. However, given that this was an observational study, the association of baseline apoB level and long-term MACEs only was evaluated; it is unclear whether the emergence of MACEs would be influenced by the dynamic changes of apoB. Because this was a retrospective and observational analysis, bias in data analysis was unavoidable; thus, the results cannot be used to generalize implications to broader patient populations, and more large-scale clinical trials are required to verify these findings.(Clin Ther. 2022;44:1071-1092) (c) 2022 Elsevier HS Journals, Inc. (Clin Ther. 2022;44:1071-1092.)(c) 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC -ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

Apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol

Combined Use of Apolipoprotein B/apolipoprotein A1 Ratio and Non-High-density Lipoprotein Cholesterol Before Routine Clinical Lipid Measurement in Predicting Coronary Heart Disease.

Association Between Non-High-density Lipoprotein Cholesterol and Coronary Artery Disease in Patients with Acute Coronary Syndrome: a Single-Centre Retrospective Cross-Sectional Analysis

Whether the combination of ApoB/ApoA1 ratio and non-HDL/HDL ratio can better predict cardiovascular risks and severity of coronary stenosis in Chinese patients with acute myocardial infarction

The Correlation between Lipids Ratio and Degree of Coronary Artery Stenosis

Apolipoprotein B/A1 Ratio is Associated with Severity of Coronary Artery Stenosis in CAD Patients but Not in Non-CAD Patients Undergoing Percutaneous Coronary Intervention

Relationship between ApoB/ApoA-I ratio and carotid atherosclerotic plaque

The relation between ApoB/ApoA-1 ratio and the severity of coronary artery disease in patients with acute coronary syndrome

Combined use of high-sensitivity C-reactive protein and apolipoprotein B/apolipoprotein A-1 ratio prior to elective coronary angiography and oral glucose tolerance tests.

Correlation between LDL-C/HDL-C Ratio and the Severity of Coronary Artery Lesion in Patients with Coronary Heart Disease

Relationship Between Non–high-Density Lipoprotein Cholesterol/apolipoprotein A-I and Monocyte/high-Density Lipoprotein Cholesterol Ratio and Coronary Heart Disease

Association Between the Non-high-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio and the Risk of Coronary Artery Disease

ApoB/apoA1 is an Effective Predictor of Coronary Heart Disease Risk in Overweight and Obesity

[Clinical Value of Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol in Assessing Risks of Coronary Artery Disease].

[Value of Glycosylated Hemoglobin A1c and Apolipoprotein A-1 Ratio on Predicting Outcome of Patients with Acute Coronary Syndrome].

Is the Ratio of Apob/apoa-1 the Best Predictor for the Severity of Coronary Artery Lesions in Chinese Diabetics with Stable Angina Pectoris? an Assessment Based on Gensini Scores.

Diagnostic value of the ratio between serum lipid and high density lipoprotein cholesterol for coronary heart disease

The value of HDL particles,the concordance of HDL-C and apoA-Ⅰ in assessing the severity of coronary artery disease

The Value of the Apolipoprotein B/Apolipoprotein A1 Ratio in Predicting the Rapid Progression of Non-Culprit Coronary Lesions in Acute Coronary Syndrome in Patients with Diabetes Mellitus after Percutaneous Coronary Intervention

Apolipoprotein B Displays Superior Predictive Value Than Other Lipids for Long-Term Prognosis in Coronary Atherosclerosis Patients and Particular Subpopulations: A Retrospective Study.

Triglyceride-to-HDL Cholesterol Ratio. Predictive Value for CHD Severity and New-Onset Heart Failure.